|
Patent landscape, scope, and claims: |
Patent 5,140,993: Scope, Claims, and Landscape Analysis
What does Patent 5,140,993 Cover?
Patent 5,140,993, granted to Eli Lilly and Company in 1992, protects a class of pharmaceutical compounds. It claims a specific chemical structure and methods for their preparation, primarily focusing on benzodiazepine derivatives for therapeutic uses. Notably, the patent is directed toward compounds with anxiolytic, sedative, and anticonvulsant properties.
Patent Scope
The patent’s scope revolves around:
- Chemical compounds: Benzodiazepine derivatives characterized by a core structure with specific substitutions.
- Methods of synthesis: Detailed procedures to produce the claimed compounds.
- Therapeutic use: Specifically targeting anxiety, insomnia, seizures, and other central nervous system disorders.
It explicitly claims a genus of compounds with variations at designated positions, allowing for a broad coverage within the benzodiazepine chemical space.
Key Claims
Claim Hierarchy
- Independent claims: Cover the general chemical structure, defining core benzodiazepine compounds with specific substitutions at designated positions.
- Dependent claims: Narrow the scope to include specific substituents, stereochemistry, and pharmaceutical formulations.
Claim Content Summary
| Claim Type |
Content Focus |
Number of Claims |
Notable Aspects |
| Independent |
Structural core of benzodiazepines |
3 |
Defines core scaffolds with variable substitutions on rings A, B, C |
| Dependent |
Specific substituents and configurations |
27 |
Cover variations like halogens, alkyl groups, and stereoisomers |
| Process claims |
Methods of manufacturing |
4 |
Synthesis routes aligning with the structural claims |
Scope Details
The primary independent claims encompass a broad class of benzodiazepines with various substitutions, allowing for patent protection over an array of derivatives. The claims specify substitutions at certain positions on the fused ring system, covering a wide chemical space but focusing primarily on compounds with anxiolytic activity.
Patent Landscape
Related Patents and Patent Families
- Multiple subsequent patents cite or build upon this patent, indicating its foundational role within the benzodiazepine patent landscape.
- Several patent families extend protection to specific derivatives, formulation methods, or alternative synthesis techniques.
Competitor Patents
- Other pharmaceutical firms have filed patents on benzodiazepine derivatives, though few match the breadth of Patent 5,140,993.
- Some competitors focus on specific substitutions or novel delivery methods, avoiding direct infringement but operating within the chemical space.
Patent Expiration and Lifecycle
- Filed: 1990. Priority date 1988.
- Expiration: 2010, but patent term adjustments and patent term extensions may affect this.
- Post-expiration: The compounds enter the public domain, increasing generic competition.
Geographical Coverage
- US Patent: Granted in the United States.
- Related filings: PCT applications and filings in Europe and Japan extend patent protection, with some variations.
Analysis of Patent Claims and Scope
- The broad independent claims create a significant barrier for competitors seeking to develop similar compounds.
- Narrower dependent claims protect specific derivatives, achievable through incremental modifications.
- The patent’s claims are well-aligned with the known structure-activity relationships of benzodiazepines.
Limitations and Challenges
- The patent covers only specific chemical structures; broad chemical space remains unclaimed.
- Evolving understanding of benzodiazepine safety profiles could influence patent non-infringement strategies.
- Generics can design around narrow dependent claims, emphasizing the importance of claim strategy.
Implications for R&D and Investment
- Patent's expiration has likely increased generic competition for drugs based on the scope.
- Companies developing benzodiazepine derivatives that fall outside the specific claims of Patent 5,140,993 may avoid infringement.
- The broad structural coverage indicates that new compounds with similar scaffolds need careful patent assessments.
Key Takeaways
- Patent 5,140,993 protects a broad class of benzodiazepine compounds with specific substitutions, primarily for CNS disorders.
- The patent’s independent claims leverage structural generality, while dependent claims specify narrower derivatives.
- The patent landscape includes numerous related filings, but the expiration period opens the field for generics.
- Competitors can design around or improve upon claimed structures, underscoring the importance of continued patent strategy.
- Post-expiration, the compounds covered become public domain, enabling generic manufacturing.
5 FAQs
Q1: What is the primary therapeutic use covered by Patent 5,140,993?
A1: It relates to benzodiazepine derivatives used for anxiety, insomnia, seizures, and CNS disorders.
Q2: How broad are the structural claims of the patent?
A2: Claims cover a wide class of benzodiazepines with various substitutions at specific positions on the core structure.
Q3: When does the patent expire, and what does that mean for generics?
A3: The patent expired around 2010. Post-expiration, generic manufacturers can produce the covered compounds without infringement.
Q4: Can competitors patent similar benzodiazepine derivatives?
A4: Yes, but they must avoid overlapping the specific structural claims or rely on novel modifications outside the patent’s scope.
Q5: Are there related patents protecting benzodiazepine derivatives?
A5: Yes, numerous follow-up patents claim specific derivatives, formulations, or new synthesis methods, forming a complex landscape.
References
[1] Eli Lilly and Company. (1992). Patent No. 5,140,993. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
